

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPplus currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8       For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:06:08 ON 28 AUG 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:06:17 ON 28 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2

DICTIONARY FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10516938.str



```

chain nodes :
1  2  3  4  5  6  7  8
ring nodes :
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
chain bonds :
1-2  2-3  3-4  4-5  4-6  6-7  6-8  8-12  9-15  19-24
ring bonds :
9-10  9-14  10-11  11-12  12-13  13-14  15-16  15-19  16-17  17-18  18-19  20-21
20-25  21-22  22-23  23-24  24-25
exact/norm bonds :
1-2  2-3  3-4  4-5  4-6  6-8  9-15  15-16  15-19  16-17
exact bonds :
6-7  8-12  17-18  18-19  19-24
normalized bonds :
9-10  9-14  10-11  11-12  12-13  13-14  20-21  20-25  21-22  22-23  23-24  24-25

isolated ring systems :
containing 9 : 15 : 20 :
```

```


Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:Atom
10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom
22:Atom  23:Atom  24:Atom  25:Atom
```

L1        STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1                STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.46

0.67

FILE 'CAPLUS' ENTERED AT 13:06:51 ON 28 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Aug 2008 VOL 149 ISS 9

FILE LAST UPDATED: 27 Aug 2008 (20080827/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s L1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 13:06:55 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 37 TO ITERATE

100.0% PROCESSED 37 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01



L2 4 SEA SSS FUL L1

L3 3 L2

=> d ibib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:370913 CAPLUS Full-text  
DOCUMENT NUMBER: 140:375166  
TITLE: Preparation of nitric oxide releasing selective  
cyclooxygenase-2 inhibitors  
INVENTOR(S): Wang, Zhaoyin; Young, Robert N.; Zamboni, Robert  
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.  
SOURCE: PCT Int. Appl., 57 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004037798	A1	20040506	WO 2003-CA1605	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503063	A1	20040506	CA 2003-2503063	20031021
AU 2003278039	A1	20040513	AU 2003-278039	20031021
EP 1562914	A1	20050817	EP 2003-769122	20031021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060058363	A1	20060316	US 2005-530214	20050404
PRIORITY APPLN. INFO.:			US 2002-420292P	P 20021022
			WO 2003-CA1605	W 20031021
OTHER SOURCE(S):	MARPAT	140:375166		
GI				



AB Novel compds. of formulas I and II [R = H, alkyl; L = bond, alkylidene, cycloalkylidene, aryl, etc.; X = O, S; Y = bond, S, O, (substituted) NH; m = 0-4; n = 1-2; p = 1-4] are prepared, which are nitric oxide-releasing prodrugs useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compns. and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compds. I or II. The above compds. may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.


IT 685107-04-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrosated or nitrosylated prodrugs for cyclooxygenase-2 inhibitors)

RN 685107-04-4 CAPLUS

CN Acetamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-2-(nitrooxy)- (CA INDEX NAME)



TITLE: Preparation of nitrooxy derivatives of cyclooxygenase-2 inhibitors  
 INVENTOR(S): Del Soldato, Piero; Santus, Giancarlo  
 PATENT ASSIGNEE(S): Nicox S.A., Fr.  
 SOURCE: PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000781	A2	20031231	WO 2003-EP6502	20030620
WO 2004000781	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2002MI1391	A1	20031229	IT 2002-MI1391	20020625
CA 2491209	A1	20031231	CA 2003-2491209	20030620
AU 2003245972	A1	20040106	AU 2003-245972	20030620
EP 1517889	A2	20050330	EP 2003-738069	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662490	A	20050831	CN 2003-814682	20030620
JP 2005530836	T	20051013	JP 2004-514803	20030620
NZ 537043	A	20060929	NZ 2003-537043	20030620
ZA 2004010060	A	20051020	ZA 2004-10060	20041213
MX 2004PA12851	A	20050224	MX 2004-PA12851	20041216
NO 2005000346	A	20050228	NO 2005-346	20050121
US 20060106082	A1	20060518	US 2005-516938	20050913
PRIORITY APPLN. INFO.:			IT 2002-MI1391	A 20020625
			WO 2003-EP6502	W 20030620

OTHER SOURCE(S): MARPAT 140:59410

AB Disclosed are new compds. able to release COX-2 inhibitors and NO (no data) having formula M-T-YA-NO<sub>2</sub> [wherein M-T = the residue of a COX-2 selective inhibitor (T = SO<sub>2</sub>NH, SO<sub>2</sub>NR, CO, O, S, NH, N(SO<sub>2</sub>R); R = C<sub>1</sub>-10 alkyl; the COX-2 selective inhibitor, M-TH or M-TOH, has to meet test 2 mentioned in the description); YA = -(B)b<sub>0</sub>-(C)c<sub>0</sub>- [b<sub>0</sub>, c<sub>0</sub> = 0,1, with the proviso that b<sub>0</sub> and c<sub>0</sub> cannot be simultaneously 0; B = TB-X<sub>2</sub>-TB<sub>1</sub>; TB = CO, X; X = O, S, NH, NR, R (defined above); TB = CO when T = SO<sub>2</sub>NH, SO<sub>2</sub>NR-O, S, NH, or N(SO<sub>2</sub>R), TB = X when T = CO; TB<sub>1</sub> = CO or X (defined above); X<sub>2</sub> = a divalent radical selected from the following compds. Q or Q<sub>1</sub>, etc. (n<sub>1</sub>, n<sub>2</sub> = 0, 1; R<sub>2</sub>, R<sub>3</sub> = H, Me; Y<sub>1</sub> = CH<sub>2</sub>CH<sub>2</sub>, CH:CH(CH<sub>2</sub>)n<sub>2</sub>; n<sub>2</sub> = 0, 1)]] for the treatment and/or prophylaxis of inflammatory disorders, pain, fever, cardiovascular disease, gastrointestinal disorders, tumors, Alzheimer's disease, or disorders resulting from elevated levels of COX-2. These compds. including 5-nitroxyptentanoc acid, 4-nitrooxybutyric acid, and 4-nitrooxybutyramide, 2-nitroxymethylbenzoic acid ester derivs. mitigate or remove the known side-effects of COX-2 inhibitors. The inflammatory disorders are selected from the group consisting of, but not limited to, arthritis, rheumatoid arthritis, osteoarthritis, allergic rhinitis, sinusitis, chronic obstructive pulmonary diseases, dermatitis, psoriasis, cystic fibrosis, multiple sclerosis, vasculitis and organ

transplant rejection. The cardiovascular diseases are selected from the group consisting of, but not limited to, atherosclerosis, restenosis, coronary artery disease, angina, diabetes mellitus, diabetic nephropathy, diabetic retinopathy, stroke and myocardial infarct. The gastrointestinal disorders are selected from the group consisting of, but not limited to, inflammatory intestinal disorders, Crohn's disease, gastritis, ulcerative colitis, peptic ulcer, hemorrhagic ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison's syndrome, bacterial infections, hypersecretory states associated with systemic mastocytosis or basophilic leukemia and hyperhystaminemia. The disorders resulting from elevated levels of COX-2 are selected from the group consisting of, but not limited to, angiogenesis, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, neoplasia, ophthalmic diseases, pulmonary inflammations, central nervous system disorders, allergic rhinitis, atherosclerosis, endothelial disorders, organs and tissues preservation, inhibition and/or prevention of platelets aggregation. Thus, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(chloro)butyroyloxymethyl]methanesulfonamide. A solution of chloromethyl (4-chloro)butyrate (1 g, 5.40 mmol) in anhydrous THF (5 mL) was slowly added dropwise in a suspension of N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]methanesulfonamide sodium salt (2.04 g, 5.40 mmol) in anhydrous THF (25 mL) and stirred at room temperature overnight to give, after workup and silica gel chromatog., N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(chloro)butyroyloxymethyl]methanesulfonamide (I). A solution of I (1 g, 1.98 mmol) in MeCN (20 mL) was added with AgNO<sub>3</sub> (0.67 g, 3.96 mmol), heated at 80° for 15 h in the absence of light, filtered to remove the silver salt, evaporated under vacuum, and purified by chromatog. on a silica gel column to give with n-hexane/ethyl acetate 8/2 as eluent to give 503 mg N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-5-yl]-N-[4-(nitrooxy)butyroyloxymethyl]methanesulfonamide.


IT 586347-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrooxy derivs. of cyclooxygenase-2 inhibitors for treatment and/or prophylaxis of inflammatory disorders, pain, fever, cardiovascular disease, gastrointestinal disorders, tumors, or Alzheimer's disease)

RN 586347-45-7 CAPLUS

CN Butanamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-4-(nitrooxy)- (CA INDEX NAME)





TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

INVENTOR(S): Scaramuzzino, Giovanni

PATENT ASSIGNEE(S): Italy

SOURCE: Eur. Pat. Appl., 313 pp.  
CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213
GI				



AB New pharmaceutical compds. of general formula F-(X)<sub>q</sub> (I) [q = 1-5, preferably 1; F is chosen among drugs such as  $\delta$ -tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO<sub>2</sub>, nitrate salt, nitrite ester, ONO, thioinitrite, SNO, etc., T = OR<sub>1</sub>-M, OR<sub>1</sub>OR<sub>1</sub>-M, SR<sub>1</sub>NR<sub>2</sub>R<sub>1</sub>-M, NR<sub>2</sub>R<sub>1</sub>-M, NR<sub>2</sub>R<sub>1</sub>SR<sub>1</sub>-M, etc., R<sub>1</sub> = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R<sub>2</sub> = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R<sub>1</sub>, R<sub>2</sub> = OH, SH, F, Cl, Br, OPO<sub>3</sub>H<sub>2</sub>, CO<sub>2</sub>H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M<sub>2</sub>, OZ-M<sub>2</sub>, NR<sub>2</sub>Z-M<sub>2</sub>, R<sub>1</sub>Z-M<sub>2</sub>, OR<sub>1</sub>-M<sub>2</sub>, OR<sub>1</sub>Z-M<sub>2</sub>, M<sub>2</sub> = M, R<sub>1</sub>-M, OR<sub>1</sub>-M, SR<sub>1</sub>-M, NR<sub>2</sub>R<sub>1</sub>-M; ZM<sub>2</sub> = COCH<sub>2</sub>CH(M<sub>2</sub>)CH<sub>2</sub>N+Me<sub>3</sub>, COCH<sub>2</sub>CH<sub>2</sub>COM<sub>2</sub>, COCH(NHR<sub>2</sub>)CH<sub>2</sub>M<sub>2</sub>, etc.; Y = 4-COC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ONO<sub>2</sub>, O(CH<sub>2</sub>)<sub>4</sub>ONO<sub>2</sub>, COCH(NH<sub>2</sub>)CH<sub>2</sub>ONO<sub>2</sub>, 3-OC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ONO<sub>2</sub>, etc.] were prepared For example,  $\alpha$ -tocopherol reacted with 4-HO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>ONO<sub>2</sub> to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.


IT 586347-45-7P 586347-46-8P 586347-62-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)


RN 586347-45-7 CAPLUS

CN Butanamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-4-(nitrooxy)- (CA INDEX NAME)




RN 586347-46-8 CAPLUS

CN Butanoic acid, 4-[[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-2,3-bis(nitrooxy)-4-oxo- (CA INDEX NAME)



RN 586347-62-8 CAPLUS

CN Butanamide, N-[[4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-4-(nitrooxy)- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
16.83	196.34

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.40	-2.40

CA SUBSCRIBER PRICE

FILE 'MARPAT' ENTERED AT 13:07:32 ON 28 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 7 (20080822/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES  
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20080167493 10 JUL 2008  
DE 102007009957 03 JUL 2008  
EP 1939208 02 JUL 2008  
JP 2008159496 10 JUL 2008  
WO 2008086729 24 JUL 2008  
GB 2444641 11 JUN 2008  
FR 2910897 04 JUL 2008  
RU 2330028 27 JUL 2008  
CA 2615024 14 JUN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT  
have increased from 100,000 to 200,000 for both on-line and batch  
searches. For more information on MARPAT search limits, type HELP  
SLIMITS at an arrow prompt.

=> s L1 SSS full

FULL SEARCH INITIATED 13:07:38 FILE 'MARPAT'  
FULL SCREEN SEARCH COMPLETED - 131 TO ITERATE

100.0% PROCESSED 131 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

L4 1 SEA SSS FUL L1

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:y  
STN INTERNATIONAL LOGOFF AT 13:07:47 ON 28 AUG 2008